A randomised, double-blind comparison of 20 units of onabotulinumtoxinA with 30 units of incobotulinumtoxinA for glabellar lines

被引:25
作者
Moers-Carpi, Marion [1 ]
Dirschka, Thomas
Feller-Heppt, Gabrielle [2 ]
Hilton, Said [3 ]
Hoffmann, Klaus [4 ]
Philipp-Dormston, Wolfgang G. [5 ]
Ruetter, Anita [6 ]
Tan, Kelvin [7 ]
Chapman, Mary Ann [8 ]
Fulford-Smith, Antony [7 ]
机构
[1] Hautok & Hautok Cosmet, D-8033 Munich, Germany
[2] Haut & Laserzentrum, Baden Baden, Germany
[3] Med Skin Ctr, Dusseldorf, Germany
[4] Ruhr Univ Bochum, Bochum, Germany
[5] Klin Links Rhein, Cologne, Germany
[6] Praxisklin Dr Med Anita Rutter, Munster, Germany
[7] Allergan, Marlow, Bucks, England
[8] Visage Commun, Mead, WA USA
关键词
glabellar lines; botulinum; onabotulinumtoxinA; incobotulinumtoxinA; TOXIN TYPE-A; BIOSIMILARS; EFFICACY; PRODUCT; SAFETY;
D O I
10.3109/14764172.2012.738913
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background : Biological activity data indicate that the units of incobotulinumtoxinA are not equivalent to those of onabotulinumtoxinA. Objective: This study compared 20 units of onabotulinumtoxinA with 30 units of incobotulinumtoxinA in the treatment of glabellar lines. Methods and materials : In this multicenter, randomised, double-blind study, subjects with moderate or severe glabellar lines received a single treatment with 20 units of onabotulinumtoxinA (n = 112), or 30 units of incobotulinumtoxinA (n = 112). The primary endpoint was the percentage of subjects with a reduction of >= 1 point on the Facial Wrinkle Scale at maximum contraction as rated by injectors on day 28 post injection. The same variable was evaluated on days 84, 98, and 112. Results: At the primary endpoint, 20 units of onabotulinumtoxinA was as effective as 30 units of incobotulinumtoxinA (96% vs. 95% responders, respectively; difference in proportion of responders = 0.02, 95% confi dence interval [CI] = 0.04, 0.07). At subsequent time points, a trend towards a higher percentage of responders was observed in the group treated with 20 units of onabotulinumtoxinA. Given that the 95% CI surpassed the upper equivalence margin at these time points, equivalence was not established. Conclusion: These data support the non-interchangeability of units of onabotulinumtoxinA and incobotulinumtoxinA, and the absence of a fixed dose ratio in clinical practice.
引用
收藏
页码:296 / 303
页数:8
相关论文
共 21 条
[1]  
[Anonymous], 2010, VIST SUMM PROD CHAR
[2]  
[Anonymous], 2012, BOC SUMM PROD CHAR
[3]  
[Anonymous], VISTABEL SUMMARY PRO
[4]  
[Anonymous], BOCOUTURE SUMMARY PR
[5]   Using translational medicine to understand clinical differences between botulinum toxin formulations [J].
Aoki, K. R. ;
Ranoux, D. ;
Wissel, J. .
EUROPEAN JOURNAL OF NEUROLOGY, 2006, 13 :10-19
[6]   Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females [J].
Carruthers, A ;
Carruthers, J ;
Said, S .
DERMATOLOGIC SURGERY, 2005, 31 (04) :414-422
[7]   Dilution volume of botulinum toxin type A for the treatment of glabellar rhytides: Does it matter? [J].
Carruthers, Alastair ;
Carruthers, Jean ;
Cohen, Joel .
DERMATOLOGIC SURGERY, 2007, 33 :S97-S104
[8]   A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines [J].
Carruthers, JA ;
Lowe, NJ ;
Menter, MA ;
Gibson, J ;
Nordquist, M ;
Mordaunt, J ;
Walker, P ;
Eadie, N .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2002, 46 (06) :840-849
[9]   Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type a for patients with glabellar lines [J].
Carruthers, JD ;
Lowe, NJ ;
Menter, MA ;
Gibson, J ;
Eadie, N .
PLASTIC AND RECONSTRUCTIVE SURGERY, 2003, 112 (04) :1089-1098
[10]   Measuring the potency labelling of onabotulinumtoxinA (BotoxA®) and incobotulinumtoxinA (XeominA®) in an LD50 assay [J].
Dressler, Dirk ;
Mander, Gerd ;
Fink, Klaus .
JOURNAL OF NEURAL TRANSMISSION, 2012, 119 (01) :13-15